In-depth evaluation of automated non-contact reflectance-based hematocrit prediction of dried blood spots
Boffel et al.
The finding, in our words
The authors validated a quadratic calibration model for automated UV-Vis-based haematocrit prediction from dried blood spots, achieving bias below 0.025 L L-1 and total precision of 2.7%. In therapeutic drug monitoring of tacrolimus, predicted haematocrit values showed good concordance with reference Sysmex measurements, supporting the use of this patient-centric microsampling approach for decentralised immunosuppressant monitoring.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Automated dried blood spot analysis achieved clinical and analytical acceptance criteria for tacrolimus, sirolimus, everolimus and cyclosporin A after haematocrit correction. This validates a method that could enable decentralised, patient-centric therapeutic drug monitoring for transplant recipients.
Clinical validation for tacrolimus and mycophenolic acid monitoring showed that while volumetric absorptive microsampling met analytical criteria after concentration correction, conventional dried blood spots achieved superior adherence to strict clinical criteria, sample quality, and cost efficiency without significant haematocrit bias.
A new LC-MS/MS method quantifies four immunosuppressants from one 3.2 mm dried blood spot using cold-induced phase separation, achieving accurate results and favourable interchangeability with a certified whole blood method in 120 paired clinical samples, supporting decentralised therapeutic drug monitoring.
The study validated a dried blood spot assay for five immunosuppressants on two LC-MS/MS systems, showing that haematocrit effects stayed within 15% across a clinically relevant range (0.23–0.48 l/l) without correction. Clinical validation confirmed that tacrolimus and cyclosporin A results from dried blood spots matched those from conventional whole blood, supporting home-based therapeutic drug monitoring without haematocrit adjustment.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.